Psychedelic treatments move closer to mainstream at FDA
• The Food and Drug Administration is seeking public input on the potential for supervised therapeutic use of psychedelic drugs. • Current federal laws classify hallucinogens like psilocybin and MDMA as Schedule I drugs, meaning they are legally defined as having no accepted medical use. • This classification creates bureaucratic red tape that makes medical research into these treatments slow and difficult for scientists.
washingtontimes.com




